24時間受付中
Wegovy (Semaglutide)|Online Prescription|0.25 mg from 18,000 JPY per pen (4 doses)|Consultation & Shipping Free
GLP-1 Receptor Agonist|Wegovy Injection
Wegovy (Semaglutide)|Online Prescription|0.25 mg from 18,000 JPY per pen (4 doses)|Consultation & Shipping Free
Once-weekly self-injection to support weight management
- Nationwide delivery to your home
- Fully online flow through to prescription
- Once-weekly subcutaneous injection (titrate 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg)
- Multi-dose pen — each pen contains 4 doses (4 weeks’ supply)
[Doctor’s Overview] What is “Wegovy”?
Wegovy (semaglutide) is a GLP-1 receptor agonist designed for once-weekly dosing. It supports appetite control and post-meal glucose regulation, enabling sustainable weight management. Treatment typically starts at 0.25 mg and is escalated stepwise depending on tolerability (follow your physician’s instructions). Each multi-dose (MD) pen contains 4 doses, providing approximately one month’s supply per pen.
Use on the same weekday. Easy to fit into busy schedules.
Each MD pen delivers 4 weekly doses — roughly one month per pen.
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, adjusted with attention to GI symptoms.
Consultation & shipping are free. Refrigerated shipping and alcohol swabs available.
Process to online prescription
Three simple steps on your phone. Same-day consults available; nationwide delivery.
How to use (follow your doctor’s instructions)
Remove from the refrigerator; check appearance and expiry. Clean the abdomen, thigh, or upper arm, and rotate sites each time.
Press the pen vertically and inject as instructed. Keep it pressed for a few seconds after the signal.
Start at 0.25 mg; escalate stepwise per tolerability. If GI symptoms are significant, consult your physician for adjustments.
Watch for nausea, vomiting, diarrhea/constipation, or abdominal pain. If severe symptoms occur, stop and seek care.
* Always follow your physician’s instructions and official package insert.
Pricing
*MD (Multi-Dose) Pens only.
Combination therapy (when appropriate)
Your physician may suggest add-ons based on your profile. Examples that can be synergistic:
Aim: Increase urinary glucose excretion to reduce net calories.
Best for: Frequent snacks / limited time to exercise.
Aim: Temper appetite impulses and support adherence.
Best for: Evening overeating / compulsive snacking.
Aim: Reduce hepatic gluconeogenesis and improve insulin resistance.
Best for: Higher fasting glucose / weight-neutral preference.
Aim: Support bowel movement and fluid balance—useful for constipation/edema patterns.
Best for: Constipation / edema / dietary reset.
FAQ
When might I feel an effect?
Any side effects?
Can I take it with other medicines?
Where can I inject?
How many doses are in one pen?
Can I purchase like online shopping?
Do I need a Japanese address or residence card?
Can I use a foreign credit card?
Can you ship to my hotel or Airbnb?
Can I consult before arriving in Japan?
I do not have a Japanese phone number. How can I have the consultation?
Can my family or friend in Japan receive the delivery on my behalf?
Can I get an English Doctor Letter for customs?
Can I order several months of supply at once?
Can I use this during pregnancy or breastfeeding?
What should I do if I miss a dose?
What if side effects are strong?
How is Wegovy different from Ozempic and Mounjaro?
Which type of pen do you prescribe?
Can I get Wegovy even if I do not have obesity?
How soon will I see results?
About the Medicine We Prescribe (Wegovy)
Wegovy (semaglutide) is approved by PMDA in Japan for obesity treatment (2023). Prescribed off-label may apply for cases outside indication criteria; treated as self-pay treatment.
We use Novo Nordisk products obtained through licensed Japanese pharmaceutical wholesalers only. We do NOT use personal imports or overseas sources.
Zepbound (tirzepatide, 2024 approval), Ozempic (semaglutide, diabetes indication).
Approved by FDA (2021, US) and EMA (2022, EU) for chronic weight management. Common side effects: nausea, diarrhea, vomiting, constipation. Rare: pancreatitis, gallbladder disease.
Off-label / self-pay usage is NOT covered by Japan’s Adverse Drug Reaction Relief System.
Generic name: Semaglutide / Class: GLP-1 receptor agonist / Form: Prefilled pen / Doses: 0.25/0.5/1.0/1.7/2.4 mg / YJ code: 2499416G1024. Refer to package insert for full information.
How Wegovy Works
Wegovy is a once-weekly injectable medicine for obesity treatment. Its active ingredient, semaglutide, is a GLP-1 receptor agonist that reduces appetite, promotes satiety, and slows gastric emptying. It is FDA-approved (2021) for chronic weight management and PMDA-approved (March 2023) for obesity treatment in Japan.
Reference: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021.
